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Chemical and Biological Differences of ALA and MAL for Photodynamic Diagnosis
and Photodynamic Therapy
R-M Szeimies
Department of Dermatology, Regensburg University Hospital, Germany
Photodynamic therapy (PDT) is a well documented and established treatment
option for epithelial skin cancer like basal cell carcinoma (BCC) and actinic
keratoses (AK). PDT induces selective tissue necrosis that occurs upon illumination
with red light; this based upon the induction of reactive oxygen species upon
activation of synthesized porphyrins. The best studied photosensitizers so far for
topical application are 5-aminolevulinic acid (ALA) and methyl aminolevulinate
(MAL). MAL is the methyl ester of ALA. The chemical modification stabilizes the
molecule thus a durable formulation (cream) is possible. In contrast, ALA
formulations must be prepared freshly. Both drugs penetrate easily abnormal
stratum corneum and are transformed to photoactivatable porphyrins within
epithelial tumors. However, there are significant differences in these processes, i.e.
penetration, intracellular uptake and porphyrin synthesis. The uptake of ALA and
consecutive porphyrin synthesis is a temperature-dependent process and shows a
maximum after 4 to 6 h. The uptake of the non-polar MAL is enhanced by
utilization of additional pathways in abnormal keratinocytes like in AK and BCC,
thus induction of porphyrins is more selective (up to 10-fold higher compared to
surrounding skin) than with ALA. It has been shown that an incubation time of 37
0.5 h with 160 mg/g MAL cream is inducing sufficient amounts of porphyrins even
in deeper layers of BCC so both photodynamic diagnosis and therapy are possible
after this incubation period. For extratemporaneous ALA formulations (20% ALA)
incubation times of 4–6 h are reported.
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Photodynamic Therapy of Non-Melanoma Skin Cancer: Update 2006
P Calzavara-Pinton, M Venturini and C Zane
Department of Dermatology, Spedali Civili, Brescia, Italy
Photodynamic therapy (PDT) is a bimodal therapeutic technique in which topical
or systemic delivery of photosensitizing drugs is followed by irradiation with visible
light. The activated sensitizer activates molecular oxygen to generate reactive
oxygen species that have a cytotoxic effect. All the photosensitizers currently under
evaluation have good selectivity, i.e. they penetrate and accumulate in tumor cells
or in the endothelium of newly formed vessels with relative sparing of the
surrounding healthy tissue. Photobiology and clinical applications of aminolevu-
linic acid (ALA) and its methyl ester (methyl-aminolevulinate, MAL) have been
investigated extensively in the past 15 years. Unlike ALA, MAL is lipophilic and its
intracellular penetration is enhanced because it exploits a plurality of efficient
mechanisms of uptake through the cell membrane. In a few randomized, controlled
multicenter studies, the application of a standard preparation containing 160 mg/gr
MAL (Metvixs, Galderma, F), followed by red light irradiation proved effective
and well tolerated in the treatment of actinic keratosis and basal cell carcinoma and
it is now approved in European countries. A proprietary ALA solution (Levulan
Kerasticks, Dusa Pharmaceuticals Inc., Wilmington, MA) plus blue light exposure
has been approved for the treatment of actinic keratosis in the USA. Randomized
and controlled studies have shown that MAL as well as ALA are also efficacious
against Bowen’s disease. In addition a large and growing number of open studies or
case reports has evaluated its use in the treatment of a broad range of other
neoplastic, inflammatory and infectious skin diseases including cutaneous T cell
lymphoma, psoriasis, acne vulgaris, hypertrichosis, warts, HPV-induced condylo-
mata, mycosis and others. However, definitive conclusions cannot be drawn and
possible advantages over standard therapies remain to be clarified because the
experimental design of these studies was generally poor and the number of enrolled
patients was low. However, these studies have suggested a few possible clinical
applications that are worthwhile of further investigations. Beside ALA and MAL, a
growing number of laboratory and clinical evidences suggest that several new
synthetic sensitizers may be helpful in the treatment of non-melanoma skin
cancers, melanoma metastasis and selected inflammatory and infective skin
diseases. These compounds are deliverable via intravenous route, have short half-
lives both in the blood and skin and high efficacy. However, they are not approved
for clinical use so far.
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Combined Therapy
R Kaufmann
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Apart from its ever rising incidence, non melanoma skin cancer is an increasing
challenge within younger people, among the growing cohort of immune
compromised individuals, particularly in those presenting with more aggressive,
larger or multiple lesions. Appropriate treatment strategies should aim at an early,
safe and also tissue sparing removal. Among the vast array of therapeutic options
having evolved for their management, recent interest has focussed on the use of
non-surgical approaches to eliminate stages of superficial tumor growth, such as
photodynamic therapy (PDT), being approved for actinic keratosis and certain basal
cell carcinomas but also helpful in others. As compared to alternatives, PDT not
only yields a selective and sufficient treatment but also can be used repetitively,
covers larger areas and targets sub-clinical foci of field cancerization. In contrast to
topical chemotherapeutic or immunotherapeutic agents time of treatment sessions
and subsequent skin irritation is limited and patients’ compliance better secured.
Therefore, in patients with multiple or shared tumor types being composed of more
superficial and deeper parts, it can be part of a multimodal concept. In such a
strategy, a combined approach will restrict conventional surgery to areas of tumor
growth, where microscopical control of resection margins is particularly essential
within the depth of the involved tissue, and allow for phototoxic destruction of
either superficial tumor components at the edges or of superficially located
adjacent additional epithelial skin cancers. Combined treatment can help to keep
excisional defects limited to a required minimum of area without hinder
appropriate cure of the entire lesion.
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MAL-PDT in Transplant Recipients
S Piaserico
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An increased frequency of neoplastic disorders is a recognized complication of
solid organ transplantation. Skin cancers are the most common malignancies
occurring in transplant recipients. In our experience based on more than 2000
organ transplant patients, the risk has been shown to increase from 16% after 5
years to 33% after 10 years in heart recipients and from 6% to 17% in kidney
recipients. The steady increase of risk of cutaneous malignancies with time after
transplantation is an alarming figure as the number of organ allograft recipients who
live for many years after transplantion is rapidly growing. This points out the need
to devote more resources to skin cancer prevention, detection and management.
Topical photodynamic therapy (PDT) represents an innovative therapeutic
approach for non surgical treatment of cutaneous precancerous lesions and skin
cancers. We evaluated the efficacy of MAL-PDT in a series of 35 organ transplant
patients affected by 205 actinic keratoses and compared it with a group of 70 not
immunosuppressed patients affected by 358 actinic keratoses. The complete
response rate of the actinic keratoses in transplanted patients was comparable to
that of the not immunosuppressed patients, reaching the 75% after 2 sessions of
photodynamic therapy. However, more than 20% of the patients exhibited at least
a recurrence of the treated lesions after 6 months. Topical photodynamic therapy
represents an effective therapeutic procedure in the treatment of actinic keratoses in
transplanted patients, but a careful follow-up is needed in order to detect early
recurrences of the treated areas.
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MAL-PDT in AK and BCC: Results of a Multicentric Italian Study
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Studi di Roma La Sapienza – II Facolta` di Medicina e Chirurgia, Roma, Italy,
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Methyl aminolevulinate photodynamic therapy (MAL-PDT) involves the use of MAL
as licensed topical photosensitiser to treat non invasively thin and non pigmented
actinic keratosis (AK) and superficial basal cell carcinoma (sBCC). MAL is a
derivative of ALA showing improved lesional selectivity and probable reduction in
pain during illumination. To determine the clinical efficacy, safety and cosmetic
outcome of MAL-PDT for small to medium sized AK and sBCC in Italian patients, a
multicentre, open label, observational, prospective study selecting 115 Caucasian
patients (76 males and 39 women, mean age 68 years) with 175 lesions (78 BCC
and 97 AK) was performed. MAL-PDT was conducted giving 2 treatments 1 week
apart. MAL cream 160 mg/g was applied after light skin curettage 3 h prior to
illumination with red light Aktilite CL 128 (light dose of 75 J/cm wavelength
635 nm). 107 individuals completed the study. The clinical complete response rate
at 3 months follow-up was 79%. Overall cosmetic outcome was judged at least
good in 82% of cases. High satisfaction level were reported from 89% of the
patients as regard to quality of life during and after treatment. Pain during
illumination and local intolerance symptoms were reported in 15% and 32% of
patients respectively: erosion, blistering and intensive pain were reported in four
cases. MAL-PDT confirmed in this study its role in the non invasive approach to AK
and sBCC with an excellent profile form a clinical real-life point of view.
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MAL-PDT for the Treatment of Large Basal Cell Carcinomas
L Eibenschutz, S Marenda, G Mariani, A Ferrari, V Silipo and C Catricala`
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Gallicano – IRCCS, Rome, Italy
We performed a retrospective non-comparative follow-up study to evaluate the
clinical response of BCCX2 cm treated with MAL-PDT. We treated 30 patients, 15
men and 15 women, affected by 37 BCC, histopathologically proven. Thirty-three
of 37 (89%) lesions were superficial BCC (sBCC), 3/37 (9%) were nodular BCC
(nBCC) and 1(3%) was mixed superficial and nodular. 4The lesions were grouped
in 3 different classes: 24 lesions with sizes ranged from 2 cm to 4 cm, 5 lesions with
maximum diameter ranged from 4 cm to 6 cm and 8 lesions larger than 6 cm.
Eleven of 37 (30%) lesions were located in ‘‘difficult-to treat’’ areas and 4 of 37
(11%) lesions were recurred after other treatments. The follow-up was performed at
least 12 months after the last treatment. The complete response rate was 97% after
3 months, 86% at 6 months and 81% after 12 months. Seven of 37 lesions including
1 mixed BCC, 1 nBCC and 5 sBCC, recurred during the follow-up. Two of the
recurrent lesions were excised whereas five were retreated with PDT. MAL-PDT is
an excellent treatment for BCC larger than 2 cm and may be considered the first
choice treatment in selected subjects for size, location and number of lesions. The
benefit of MAL-PDT are the selectivity, the tissue-sparing, the repeatability and the
excellent cosmetic results with minimal scarring.
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